Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose amitriptyline versus CBT-I for chronic insomnia with medical comorbidity
NL-OMON55662Phase 3Recruiting
- Sponsor
- Hospital Gelderse Vallei
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amitriptyline in chronic insomnia (2 arms), sponsored by Hospital Gelderse Vallei. Primary endpoint: Mean subjective insomnia severity score at 12 weeks. Started Sep 2019; status: recruiting.
02
Drugs
amitriptyline
03
Conditions
chronic insomnia
Beyond the preview
Go deeper on NL-OMON55662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55662.